Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2000

01-01-2000 | ORIGINAL ARTICLE

Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function

Authors: Claire Massari, Silvano Brienza, Mathieu Rotarski, Julio Gastiaburu, Jean-Louis Misset, Didier Cupissol, Elisabetta Alafaci, Hélène Dutertre-Catella, Gérard Bastian

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2000

Login to get access
Metadata
Title
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function
Authors
Claire Massari
Silvano Brienza
Mathieu Rotarski
Julio Gastiaburu
Jean-Louis Misset
Didier Cupissol
Elisabetta Alafaci
Hélène Dutertre-Catella
Gérard Bastian
Publication date
01-01-2000
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2000
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050024

Other articles of this Issue 2/2000

Cancer Chemotherapy and Pharmacology 2/2000 Go to the issue

ORIGINAL ARTICLE

Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer

ORIGINAL ARTICLE

Impact of the simultaneous administration of the (+)- and (−)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (−)-tetrahydrofolic acid

CLINICAL TRIAL REPORT

Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study

ORIGINAL ARTICLE

Different microtubule network alterations induced by pachymatismin, a new marine glycoprotein, on two prostatic cell lines

ORIGINAL ARTICLE

Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation

ORIGINAL ARTICLE

Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits